Related Experiment Video
Updated: Aug 7, 2026
05:20
Separation of Plasmodium falciparum Late Stage-infected Erythrocytes by Magnetic Means
Published on: March 2, 2013
[Hemolysis and primaquine treatment. Preliminary report]
R Menéndez Capote1, L Díaz Pérez, C Luzardo Suárez
1Instituto de Medicina Tropical Pedro Kourí.
Revista Cubana De Medicina Tropical
|January 1, 1997
Summary
Primaquine treatment for Plasmodium vivax malaria can cause severe hemolysis in patients with glucose-6-phosphate dehydrogenase deficiency. Many patients could not complete this radical treatment due to adverse effects.
Area of Science:
- Hematology
- Infectious Diseases
- Pharmacology
Background:
- Plasmodium vivax malaria requires radical treatment to prevent relapse.
- Primaquine is a key drug for radical treatment but can cause hemolysis.
- Glucose-6-phosphate dehydrogenase (G6PD) deficiency increases hemolysis risk with primaquine.
Purpose of the Study:
- To investigate the incidence and severity of hemolysis in G6PD-deficient patients undergoing primaquine treatment for P. vivax malaria.
- To assess the safety and tolerability of primaquine in this patient population.
Main Methods:
- Studied 8 patients diagnosed with P. vivax malaria and G6PD deficiency.
- Monitored patients for hemolysis during primaquine antimalarial therapy.
- Assessed the relationship between hemolysis and G6PD enzymatic activity.
Main Results:
- 87.5% of patients experienced hemolysis.
- Hemolysis severity was not significantly correlated with G6PD enzymatic activity (p > 0.05).
- 50% of patients discontinued treatment due to significant hemolysis.
Conclusions:
- Primaquine should be used with caution in G6PD-deficient individuals.
- Indiscriminate use of primaquine in G6PD-deficient patients is not recommended due to high risk of severe hemolysis.
- Alternative radical treatment strategies may be necessary for this patient group.
